{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:28:16Z","timestamp":1776371296640,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["EH received funding as a clinician scientist \u201eForschungskolleg Therapieresistenz solider Tumoren\u201c"],"award-info":[{"award-number":["EH received funding as a clinician scientist \u201eForschungskolleg Therapieresistenz solider Tumoren\u201c"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>5\u2011Fluoruracil (5-FU) and its oral prodrug capecitabine are mainstays in combined chemoradiotherapy regimens. They are metabolized by dihydropyrimidine dehydrogenase (DPYD). Pathogenic variants of the <jats:italic>DPYD<\/jats:italic> gene cause a\u00a0reduction in DPYD activity, leading to possibly severe toxicities. Therefore, patients receiving 5\u2011FU-\/capecitabine-based chemoradiotherapy should be tested for <jats:italic>DPYD<\/jats:italic> variants. However, there are limited clinical data on treatment adjustments and tolerability in patients with decreased DPYP activity receiving combined chemoradiotherapy. Therefore, a\u00a0retrospective analysis of the toxicity profiles of patients with decreased DPYD activity treated at our center was conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>For all patients receiving 5\u2011FU-\/capecitabine-based chemo(radio)therapy at our department, DPYD activity was routinely tested. Genotyping of four <jats:italic>DPYD<\/jats:italic> variants (<jats:italic>DPYD*2A, DPYD*13, c.2846A<\/jats:italic>\u202f<jats:italic>&gt;<\/jats:italic>\u2009<jats:italic>T<\/jats:italic>, and haplotype B3) was conducted according to the recommendation of the German Society for Hematooncology (DGHO) using TaqMan hydrolysis polymerase chain reaction (PCR; QuantStudy\u00a03, Thermo FisherScientific, Darmstadt). <jats:italic>DPYD <\/jats:italic>variants and activity score as well as clinical data (tumor entity, treatment protocol, dose adjustments, and toxicity according to the Common Terminology Criteria for Adverse Events [CTCAE]) were assessed and reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 261 tested patients, 21\u00a0exhibited <jats:italic>DPYD <\/jats:italic>variants, 18\u00a0of whom received chemoradiotherapy. All but one patient was treated for rectal or anal carcinoma. The observed rate of <jats:italic>DPYD<\/jats:italic> variants was 8.0%, and heterozygous haplotype B3 was the most common (5.75%). One patient exhibited a\u00a0homozygous <jats:italic>DPYD<\/jats:italic> variant. DPYD activity score was at least 0.5\u00a0in heterozygous patients; chemotherapy dose was adjusted accordingly, with an applied dose of 50\u201375%. CTCAE grade\u00a02 skin toxicity (50%) and grade\u00a03 leukopenia (33.3%) were most common. One patient experienced a\u00a0transient grade\u00a04 increase in transaminases. All high-grade toxicities were manageable with supportive treatment and transient. No CTCAE grade\u00a05 toxicities related to 5\u2011FU administration were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>With dose reduction in heterozygous patients, toxicity was within the range of patients without <jats:italic>DPYD<\/jats:italic> variants. Our clinical data suggest that dose-adapted 5\u2011FU-\/capecitabine-chemoradiotherapy regimens can be safely considered in patients with heterozygous clinically relevant <jats:italic>DPYD<\/jats:italic> variants, but that the optimal dosage still needs to be determined to avoid both increased toxicity and undertreatment in a\u00a0curative setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-024-02287-7","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T11:03:13Z","timestamp":1725447793000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-\/capecitabine-based chemoradiotherapy"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-919X","authenticated-orcid":false,"given":"E.","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toepell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"B\u00f6ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"De-Colle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"issue":"4","key":"2287_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/CAD.0b013e3283441a63","volume":"22","author":"PA Patel","year":"2011","unstructured":"Patel\u00a0PA (2011) Evolution of 5\u2011fluorouracil-based chemoradiation in the management of rectal cancer. Anticancer Drugs 22(4):311\u2013316","journal-title":"Anticancer Drugs"},{"key":"2287_CR2","first-page":"100672","volume":"43","author":"SM O\u2019Cathail","year":"2023","unstructured":"O\u2019Cathail\u00a0SM et\u00a0al (2023) Patient-reported outcomes in PROSPECT trial (Alliance N1048)\u2014FOLFOX is not a\u00a0panacea. Clin Transl Radiat Oncol 43:100672","journal-title":"Clin Transl Radiat Oncol"},{"key":"2287_CR3","first-page":"113","volume":"36","author":"PP Bulens","year":"2022","unstructured":"Bulens\u00a0PP et\u00a0al (2022) Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A\u00a0prospective cohort study. Clin Transl Radiat Oncol 36:113\u2013120","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2287_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.21712","volume":"72","author":"LT Tchelebi","year":"2022","unstructured":"Tchelebi\u00a0LT et\u00a0al (2022) Current treatment and future directions in the management of anal cancer. CA Cancer J Clin 72(2):183\u2013195","journal-title":"CA Cancer J Clin"},{"key":"2287_CR5","doi-asserted-by":"publisher","first-page":"109584","DOI":"10.1016\/j.radonc.2023.109584","volume":"183","author":"A de Haar-Holleman","year":"2023","unstructured":"de Haar-Holleman\u00a0A et\u00a0al (2023) Chemoradiation for muscle-invasive bladder cancer using 5\u2011fluorouracil versus capecitabine: A\u00a0nationwide cohort study. Radiother Oncol 183:109584","journal-title":"Radiother Oncol"},{"issue":"5","key":"2287_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","volume":"17","author":"AM Buckley","year":"2020","unstructured":"Buckley\u00a0AM et\u00a0al (2020) Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol 17(5):298\u2013313","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"2287_CR7","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie\u00a0GD et\u00a0al (1987) Clinical pharmacokinetics of 5\u2011fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47(8):2203\u20132206","journal-title":"Cancer Res"},{"key":"2287_CR8","unstructured":"EMA https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeloda-epar-product-information_en.pdf. Accessed 22 Apr 2024"},{"issue":"4","key":"2287_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"MA Loriot","year":"2018","unstructured":"Loriot\u00a0MA et\u00a0al (2018) Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105(4):397\u2013407","journal-title":"Bull Cancer"},{"key":"2287_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2022.11.028","volume":"181","author":"MC Etienne-Grimaldi","year":"2023","unstructured":"Etienne-Grimaldi\u00a0MC et\u00a0al (2023) Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer 181:3\u201317","journal-title":"Eur J Cancer"},{"key":"2287_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","volume":"124","author":"B-LC Guellec","year":"2020","unstructured":"Guellec\u00a0B\u2011LC et\u00a0al (2020) Toxicities associated with chemotherapy regimens containing a\u00a0fluoropyrimidine: A\u00a0real-life evaluation in France. Eur J Cancer 124:37\u201346","journal-title":"Eur J Cancer"},{"issue":"2","key":"2287_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2515\/therapie:2007023","volume":"62","author":"E Gamelin","year":"2007","unstructured":"Gamelin\u00a0E, Boisdron-Celle\u00a0M, Morel\u00a0A (2007) Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines. Therapie 62(2):99\u2013103","journal-title":"Therapie"},{"issue":"1","key":"2287_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","volume":"44","author":"M Boisdron-Celle","year":"2017","unstructured":"Boisdron-Celle\u00a0M et\u00a0al (2017) Prevention of 5\u2011fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a\u00a0multiparametric approach. Semin Oncol 44(1):13\u201323","journal-title":"Semin Oncol"},{"key":"2287_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00118","volume":"1","author":"LM Henricks","year":"2017","unstructured":"Henricks\u00a0LM et\u00a0al (2017) Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. Jco Precis Oncol 1:1\u201310","journal-title":"Jco Precis Oncol"},{"key":"2287_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","volume":"54","author":"C Lunenburg","year":"2016","unstructured":"Lunenburg\u00a0C et\u00a0al (2016) Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer 54:40\u201348","journal-title":"Eur J Cancer"},{"issue":"1","key":"2287_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/bcp.12790","volume":"81","author":"M Launay","year":"2016","unstructured":"Launay\u00a0M et\u00a0al (2016) Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5\u2011FU in patients with digestive cancer. Br J Clin Pharmacol 81(1):124\u2013130","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2287_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma\u00a0BB et\u00a0al (2021) Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A\u00a0Systematic Review and Meta-Analysis. Oncologist 26(12):1008\u20131016","journal-title":"Oncologist"},{"issue":"11","key":"2287_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1159\/000510258","volume":"43","author":"B Wormann","year":"2020","unstructured":"Wormann\u00a0B et\u00a0al (2020) Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5\u2011Fluorouracil, Capecitabine, and Tegafur: A\u00a0Consensus Paper. Oncol Res Treat 43(11):628\u2013636","journal-title":"Oncol Res Treat"},{"issue":"2","key":"2287_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz\u00a0U et\u00a0al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 103(2):210\u2013216","journal-title":"Clin Pharmacol Ther"},{"key":"2287_CR20","unstructured":"DGHO https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/gute-aerztliche-praxis\/dpd-testung\/dpd-positionspapier-2020-konsens_logos_final.pdf. Accessed 22 Apr 2024"},{"key":"2287_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2018.07.138","volume":"104","author":"C Lunenburg","year":"2018","unstructured":"Lunenburg\u00a0C et\u00a0al (2018) Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. Eur J Cancer 104:210\u2013218","journal-title":"Eur J Cancer"},{"key":"2287_CR22","doi-asserted-by":"publisher","first-page":"175628482110244","DOI":"10.1177\/17562848211024464","volume":"14","author":"MWM Saif","year":"2021","unstructured":"Saif\u00a0MWM et\u00a0al (2021) Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes. Therap Adv Gastroenterol 14:17562848211024464","journal-title":"Therap Adv Gastroenterol"},{"key":"2287_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3389\/fonc.2020.00761","volume":"10","author":"SH Hanemaaijer","year":"2020","unstructured":"Hanemaaijer\u00a0SH et\u00a0al (2020) Comparison of Carboplatin With 5\u2011Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Front Oncol 10:761","journal-title":"Front Oncol"},{"key":"2287_CR24","unstructured":"CTCAE https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 22 Apr 2024"},{"key":"2287_CR25","first-page":"100671","volume":"43","author":"J Lee","year":"2023","unstructured":"Lee\u00a0J et\u00a0al (2023) Impact of reduced margin pelvic radiotherapy on gastrointestinal toxicity and outcome in gynecological cancer. Clin Transl Radiat Oncol 43:100671","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2287_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/2212697X04666170817123425","volume":"4","author":"M Launay","year":"2017","unstructured":"Launay\u00a0M et\u00a0al (2017) Upfront Dpd Deficiency Detection to Secure 5\u2011Fu Administration: Part\u00a02\u2014Application to Head-and-Neck Cancer Patients. Clin Cancer Drugs 4(2):122\u2013128","journal-title":"Clin Cancer Drugs"},{"issue":"1","key":"2287_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","volume":"1","author":"J Verweij","year":"1990","unstructured":"Verweij\u00a0J, Pinedo Mitomycin\u00a0HMC (1990) mechanism of action, usefulness and limitations. Anticancer Drugs 1(1):5\u201313","journal-title":"Anticancer Drugs"},{"issue":"2","key":"2287_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.adro.2019.01.005","volume":"4","author":"MD Schad","year":"2019","unstructured":"Schad\u00a0MD et\u00a0al (2019) Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer. Adv Radiat Oncol 4(2):323\u2013330","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2287_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00262-021-03002-6","volume":"71","author":"E Hoffmann","year":"2022","unstructured":"Hoffmann\u00a0E et\u00a0al (2022) Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunol Immunother 71(3):541\u2013552","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2287_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13014-019-1223-2","volume":"14","author":"G Sanguineti","year":"2019","unstructured":"Sanguineti\u00a0G et\u00a0al (2019) Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a\u00a0secondary analysis from a\u00a0randomized study. Radiat Oncol 14(1):23","journal-title":"Radiat Oncol"},{"issue":"4","key":"2287_CR31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"C Lunenburg","year":"2020","unstructured":"Lunenburg\u00a0C et\u00a0al (2020) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28(4):508\u2013517","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"2287_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/curroncol29020045","volume":"29","author":"A Desilets","year":"2022","unstructured":"Desilets\u00a0A et\u00a0al (2022) Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A\u00a0Work in Progress. Curr Oncol 29(2):497\u2013509","journal-title":"Curr Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02287-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:05:57Z","timestamp":1750410357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02287-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02287-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.\u00a0Hoffmann, A.\u00a0Toepell, A.\u00a0Peter, S.\u00a0B\u00f6ke, C.\u00a0De-Colle, M.\u00a0Steinle, M.\u00a0Niyazi, and C.\u00a0Gani declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients\u2019 consent: This study was conducted in compliance with the Declaration of Helsinki. The study was approved by and registered with the ethics committee of the University of Tubingen (959\/2021BO2). Broad consent to analyze clinical data and outcome was given. All patients agreed to genetic testing for assessing DPYD variants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}